Study of Naltrexone for Methamphetamine Addiction

The purpose of this study is to determine whether methamphetamine-dependent individuals will use less methamphetamine when treated with naltrexone. The study will also investigate whether individuals with the mu opioid receptor gene variant A118G will use less methamphetamine than individuals without A118G.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Methamphetamine Dependence

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Addiction & Pharmacology Research Laboratory

San Francisco, California, 94110, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age between 18 and 50 years
Patient is agreeable to conditions of study and signs consent form

Treatment and study plan

Naltrexone

Drug

380mg extended-release, given once by intramuscular gluteal injection

Other names: Vivitrol, Vivitrex

Primary outcomes

MA (-) Urine Samples

Time frame: Twice weekly for 5 weeks

Sponsors and collaborators

Lead sponsor

California Pacific Medical Center Research Institute

Other

Registry information

Official study title

A Pilot Trial of Naltrexone for Methamphetamine Addiction - Role of the A118G SNP

Important dates

Study start: 2009
Primary completion: 2011
Study completion: 2012
First posted: Sep 25, 2009
Registry last updated: May 31, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed